EXTON, Pa., Jan. 7, 2015 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc., (Nasdaq:FCSC), an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs, today announced that David Pernock, chairman and chief executive officer of Fibrocell Science will present at the Biotech Showcase 2015 Conference at 11:00 a.m. PT on Monday, January 12, 2015, at the Parc 55 Wyndham San Francisco Union Square Hotel. Mr. Pernock will discuss the company's therapeutic candidates using gene-modified autologous fibroblasts for orphan skin diseases that are being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.
A live webcast of the presentation will be available on Fibrocell's website at http://www.fibrocellscience.com/investors/events-and-presentations/ and archived for 30 days.
Co-produced by Demy-Colton Life Science Advisors and EBD Group, Biotech Showcase is an investor and partnering conference devoted to providing private and public biotechnology and life sciences companies an opportunity to present to, and meet with, investors and pharmaceutical executives during the course of one of the industry's largest annual healthcare investor conferences. Now in its seventh year, Biotech Showcase is expected to attract upwards of 1,500 attendees.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (Nasdaq:FCSC) is an autologous cell therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's lead orphan drug program is in late-stage pre-clinical development for the treatment of RDEB (recessive dystrophic epidermolysis bullosa). Working in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology, Fibrocell is genetically modifying autologous fibroblast cells to express target proteins that are inactive or missing from patients with rare genetic skin and connective tissue disorders. Fibrocell is also pursuing medical applications for azficel-T—the Company's proprietary autologous fibroblast technology. Currently, the Company is in a Phase II clinical trial for vocal cord scarring. For additional information, visit www.fibrocellscience.com.